Australian Clinical Labs Ltd
ASX:ACL

Watchlist Manager
Australian Clinical Labs Ltd Logo
Australian Clinical Labs Ltd
ASX:ACL
Watchlist
Price: 2.78 AUD -0.36%
Market Cap: 552m AUD

Intrinsic Value

The intrinsic value of one ACL stock under the Base Case scenario is 5.33 AUD. Compared to the current market price of 2.78 AUD, Australian Clinical Labs Ltd is Undervalued by 48%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACL Intrinsic Value
5.33 AUD
Undervaluation 48%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Australian Clinical Labs Ltd

Valuation History Unavailable

Historical valuation for ACL cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

A sharp drop in pandemic-related testing volumes threatens to crimp ACL’s revenue and margin growth, as the company’s COVID-19 tailwind fades faster than anticipated.

Bull Theses

ACL’s ability to deepen its footprint through strategic acquisitions, such as buying out smaller pathology firms, fosters economies of scale and enhances its bargaining power with suppliers.

Show More Less
How do you feel about ACL?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Australian Clinical Labs Ltd
Financials
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Australian Clinical Labs Ltd

Balance Sheet Decomposition
Australian Clinical Labs Ltd

Current Assets 122.3m
Cash & Short-Term Investments 21.6m
Receivables 71.2m
Other Current Assets 29.5m
Non-Current Assets 462.8m
Long-Term Investments 2.2m
PP&E 284.2m
Intangibles 164.8m
Other Non-Current Assets 11.6m
Efficiency

Free Cash Flow Analysis
Australian Clinical Labs Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Australian Clinical Labs Ltd

Revenue
728.3m AUD
Cost of Revenue
-127m AUD
Gross Profit
601.2m AUD
Operating Expenses
-533.8m AUD
Operating Income
67.5m AUD
Other Expenses
-36.8m AUD
Net Income
30.7m AUD
Fundamental Scores

ACL Profitability Score
Profitability Due Diligence

Australian Clinical Labs Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROIC
62/100
Profitability
Score

Australian Clinical Labs Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

ACL Solvency Score
Solvency Due Diligence

Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Average D/E
Short-Term Solvency
Positive Net Debt
24/100
Solvency
Score

Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACL Price Targets Summary
Australian Clinical Labs Ltd

Wall Street analysts forecast ACL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACL is 3.72 AUD with a low forecast of 3.18 AUD and a high forecast of 4.31 AUD.

Lowest
Price Target
3.18 AUD
14% Upside
Average
Price Target
3.72 AUD
34% Upside
Highest
Price Target
4.31 AUD
55% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ACL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ACL Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ACL stock?

The intrinsic value of one ACL stock under the Base Case scenario is 5.33 AUD.

Is ACL stock undervalued or overvalued?

Compared to the current market price of 2.78 AUD, Australian Clinical Labs Ltd is Undervalued by 48%.

Back to Top